If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,432.00
Bid: 1,438.00
Ask: 1,440.00
Change: 5.00 (0.35%)
Spread: 2.00 (0.139%)
Open: 1,425.00
High: 1,443.00
Low: 1,423.00
Prev. Close: 1,427.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
20th Feb 20237:00 amRNSTransaction in Own Shares
17th Feb 20237:00 amRNSTransaction in Own Shares
16th Feb 20233:00 pmRNSSID & Chair of Remuneration Committee
16th Feb 20237:00 amRNSFinal Results
16th Feb 20237:00 amRNSTransaction in Own Shares
15th Feb 20237:00 amRNSTransaction in Own Shares
14th Feb 20237:00 amRNSTransaction in Own Shares
13th Feb 20237:00 amRNSTransaction in Own Shares
10th Feb 20234:16 pmRNSHolding(s) in Company
10th Feb 20237:00 amRNSTransaction in Own Shares
9th Feb 20237:00 amRNSTransaction in Own Shares
8th Feb 20237:00 amRNSTransaction in Own Shares
7th Feb 20237:00 amRNSTransaction in Own Shares
6th Feb 20231:00 pmRNSHSR Period for Opiant Acquisition Expires
6th Feb 20237:00 amRNSTransaction in Own Shares
3rd Feb 20237:00 amRNSTransaction in Own Shares
2nd Feb 20237:00 amRNSTransaction in Own Shares
1st Feb 20239:14 amRNSTotal Voting Rights
1st Feb 20237:00 amRNSTransaction in Own Shares
31st Jan 20237:00 amRNSTransaction in Own Shares
30th Jan 20237:00 amRNSTransaction in Own Shares
27th Jan 20233:22 pmRNSHolding(s) in Company
27th Jan 20237:00 amRNSTransaction in Own Shares
26th Jan 20237:00 amRNSTransaction in Own Shares
25th Jan 20233:56 pmRNSHolding(s) in Company
25th Jan 20237:00 amRNSTransaction in Own Shares
24th Jan 20234:37 pmRNSTransaction in Own Shares
23rd Jan 20237:00 amRNSTransaction in Own Shares
20th Jan 20239:31 amRNSHolding(s) in Company
20th Jan 20237:00 amRNSTransaction in Own Shares
19th Jan 202311:22 amRNSHolding(s) in Company
19th Jan 20237:00 amRNSTransaction in Own Shares
18th Jan 20233:28 pmRNSHolding(s) in Company
18th Jan 20237:00 amRNSTransaction in Own Shares
17th Jan 20237:00 amRNSTransaction in Own Shares
16th Jan 20237:00 amRNSTransaction in Own Shares
13th Jan 20234:26 pmRNSHolding(s) in Company
13th Jan 20237:00 amRNSTransaction in Own Shares
12th Jan 20232:43 pmRNSHolding(s) in Company
12th Jan 20237:00 amRNSTransaction in Own Shares
11th Jan 20232:30 pmRNSNotice of Results
11th Jan 20237:00 amRNSTransaction in Own Shares
10th Jan 20231:59 pmRNSHolding(s) in Company
10th Jan 20237:00 amRNSTransaction in Own Shares
9th Jan 202312:21 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSTransaction in Own Shares
6th Jan 20237:00 amRNSTransaction in Own Shares
5th Jan 202312:26 pmRNSHolding(s) in Company
5th Jan 20238:52 amRNSDirector Declaration
5th Jan 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.